## **ä»Šæ—¥æ‘˜è¦**

```
**Refining the Approach**

I'm zeroing in on the 3-line constraint. Finding the optimal way to synthesize complex information into such a short format is the challenge, as is maintaining a friendly tone. Considering strategies to balance conciseness and clarity is now a key point. The goal is easy to read news.


**Structuring the News**

I'm now iterating on the initial draft. The first line, summarizing the major event, is proving manageable. However, synthesizing the remaining information into two concise lines while maintaining a coherent flow requires careful selection and wording. The goal is to highlight the most impactful advancements and trends.


**Formulating the Summary**

I'm now carefully crafting the final 3-line output, ensuring conciseness and impact. I'm focusing on the tone â€“ aiming for approachable and informative, not overly technical or jargon-laden. I've drafted candidate lines and am rigorously checking character counts to adhere to the limits and improve readability for the AI and Life Science audience. The final step is to combine them into one concise unit.


**Finalizing the Output**

I'm now satisfied with the 3-line summary's content, structure, and readability, as well as adherence to the strict character limits. I'm focusing on the overall message's impact on the target audience. The goal is to present actionable information with a professional and friendly voice. The last step is ensuring it is accurate and the best it can be with the constraints.


**Summarizing the News**

I'm now carefully generating the final 3-line news summary. Iâ€™m ensuring conciseness and impact, using the correct tone and character counts. I've re-reviewed the source content and the prior summary, making some adjustments to fit the format and target audience. Finally, Iâ€™ve made minor edits, particularly to sentence structure. The goal is to provide accessible information for AI and life science professionals.


**Generating the Summary**

I'm now putting the finishing touches on the final summary. I've re-reviewed the source content â€“ the MIT model, protein design trends, and metabolic models â€“ and ensured the summary reflects those key points in a clear, concise, and engaging style. The tone is meant to be direct, avoiding jargon and aiming for maximum impact. I've checked the character counts and line structure. The result is meant to be an approachable and informative digest for the target audience.


MIT å‘å¸ƒ Boltz-2 æ¨¡å‹ï¼Œè™šæ‹Ÿç­›é€‰æˆåŠŸç‡ç›´æ¥ç¿»å€ï¼Œåˆ†å­é¢„æµ‹è¿æ¥å·¥ä¸šçº§çªç ´ã€‚
è›‹ç™½è´¨è®¾è®¡å¼€å§‹ç©å¤šæ™ºèƒ½ä½“åä½œï¼ŒNature è¿å‘æ–‡è¯æ˜ AI ä¹Ÿèƒ½å¬æ‡‚ä»£è°¢è¯­è¨€ã€‚
åŸºç¡€æ¨¡å‹å®æˆ˜èƒ½åŠ›é£™å‡ï¼Œå»ºè®®é‡ç‚¹å…³æ³¨å‰ä¸¤æ¡ï¼ŒAI åˆ¶è¯æ­£åœ¨å‘Šåˆ«"ç›²ç›®ç‚¼ä¸¹"æ—¶ä»£ã€‚
```



## âš¡ å¿«é€Ÿå¯¼èˆª

- [ğŸ“° ä»Šæ—¥ AI èµ„è®¯](#ä»Šæ—¥aièµ„è®¯) - æœ€æ–°åŠ¨æ€é€Ÿè§ˆ



> ğŸ’¡ **æç¤º**ï¼šæƒ³ç¬¬ä¸€æ—¶é—´ä½“éªŒæ–‡ä¸­æåˆ°çš„æœ€æ–° AI æ¨¡å‹ï¼ˆClaude 4.5ã€GPTã€Gemini 3 Proï¼‰ï¼Ÿæ²¡æœ‰è´¦å·ï¼Ÿæ¥ [**çˆ±çªå•¦ Aivora**](https://aivora.cn?utm_source=daily_news&utm_medium=mid_ad&utm_campaign=content) é¢†ä¸ªå·ï¼Œä¸€åˆ†é’Ÿä¸Šæ‰‹ï¼Œå”®åæ— å¿§ã€‚

**Comprehending the Task**

I'm now zeroing in on the core of the request. The role, tone, and focus are clear - a veteran observer writing with an accessible style about AI and life sciences. The primary objective is to condense the provided information into a daily newsletter. I'm carefully dissecting the nuances to ensure the output aligns perfectly.


**Evaluating Input Material**

I've begun scoring the input, starting with the Google Gemini/Veo example. Given the clear instructions, the lack of a Life Sciences link means it is a definite discard. Now I am moving to the Glioblastoma content, assessing its relevance to the specified intersection.


**Processing the Content**

I'm now methodically assessing each source, considering content, relevance, and ultimately, a numeric score. The Glioblastoma paper and the graph-based RNA study are looking promising. I'm focusing on the AI and Life Science intersection, with the goal of curating information relevant to the specified audience.


**Refining Scoring and Selection**

I've finalized the scoring of the input material, meticulously assessing each piece against the criteria. I've now categorized candidates into "Top 10" and "Worth Watching" based on the scores. Now, I'm focusing on crafting the summary, prioritizing the high-scoring, high-relevance selections. I'm also ensuring the structure of the output adheres precisely to the provided guidelines, including tone and style.


**Generating the Report Structure**

I'm now establishing the structure, mapping scores to sections. The "Top 10" will be the focus, with "Worth Watching" items supporting. I'll adhere to the requested "One Sentence, Keywords" format. The two FAQs are now being drafted for the end of the report to promote the products. The "Fun" section will be included if possible.


**Curating the Final Selection**

I'm now deciding on the final "Top 10" entries, aiming for a balance of categories, with focus on drug discovery, genomics, and clinical applications. There are many high-scoring candidates, so I'm also considering presentation and easy summaries. I'm also including some Github tools.


**Refining Content Drafting**

I'm now writing the individual summaries. The "one sentence" rule is challenging, but I'm achieving that. For Boltz-2, I'm leaning toward emphasizing the enhanced success rate. The metabolite LLM is presenting a compelling narrative. I will now integrate the keywords and start the Worth Watching section.


**Synthesizing Report Content**

I'm now fully immersed in writing each summary, targeting the "one sentence, keywords" guidelines, while also aiming for an engaging tone. The Boltz-2 and metabolite LLM are strong leads, but I must also consider the most pertinent and engaging aspects for the audience. The "Worth Watching" section is next, followed by final edits for the report.


**Summarizing and Planning**

I'm now fully immersed in the task breakdown and selection, including careful evaluation. I've formulated the report structure and scored the input material, resulting in a finalized "Top 10" list and a "Worth Watching" list. The individual summaries are next, as well as the FAQ and trend analysis sections. I am ready to start the drafting, and finalize the newsletter.


**Fine-Tuning the Summary**

I'm now integrating the generated content, including the Top 10, Worth Watching, FAQs, and trend analysis, while also adding markdown for formatting. I am reviewing the draft to refine the tone, ensuring it's accessible and conversational, as well as checking and double-checking links. The goal is to provide a concise and engaging report in the required style.


**Summarizing the Core Elements**

I'm now carefully curating the final content. I've drafted all sections of the report - Top 10, Worth Watching, FAQs, and trend analysis, while also adding the markdown for formatting. I am now reviewing the report for tone and clarity. I have checked the links and am now making final adjustments to the newsletter.


## **ä»Šæ—¥ AI ç”Ÿå‘½ç§‘å­¦èµ„è®¯**

### **ğŸ‘€ åªæœ‰ä¸€å¥è¯**
AI åˆ¶è¯åœˆä»Šå¤©ç‚¸é”…äº†ï¼šBoltz-2 æ¨¡å‹æ¨ªç©ºå‡ºä¸–ï¼Œå·ç§°åœ¨è™šæ‹Ÿç­›é€‰ä¸Šçš„æˆåŠŸç‡ç›´æ¥æ˜¯ç°æœ‰æ–¹æ³•çš„ä¸¤å€ï¼Œä»¥å‰"éšç¼˜ç‚¼ä¸¹"çš„æ—¥å­å¯èƒ½è¦ç»“æŸäº†ã€‚

### **ğŸ”‘ 3 ä¸ªå…³é”®è¯**
#AIåˆ¶è¯ #ç”Ÿç‰©åŸºç¡€æ¨¡å‹ #å¤šæ™ºèƒ½ä½“åä½œ

## **ğŸ”¥ é‡ç£… TOP 10**

### 1. [Boltz-2ï¼šè™šæ‹Ÿç­›é€‰çš„"é™ç»´æ‰“å‡»"](https://www.biorxiv.org/content/10.64898/2026.01.14.699425v1?rss=1)
**åˆšæ‰è¿˜åœ¨ä¸ºè›‹ç™½è´¨-é…ä½“ç›¸äº’ä½œç”¨é¢„æµ‹æŒ å¤´ï¼Œç°åœ¨æ•‘æ˜Ÿæ¥äº†ã€‚**
MIT å’Œ Broad Institute çš„ç ”ç©¶äººå‘˜æå‡ºäº†ä¸ªå« Boltz-2 çš„æ–°æ¨¡å‹ã€‚ç®€å•æ¥è¯´ï¼Œå®ƒåœ¨é¢„æµ‹è¯ç‰©åˆ†å­èƒ½ä¸èƒ½å’Œé¶ç‚¹ç»“åˆï¼ˆè™šæ‹Ÿç­›é€‰ï¼‰è¿™ä»¶äº‹ä¸Šï¼Œè¡¨ç°å¾—å¼ºå¾—å¯æ€•ã€‚åœ¨åŒ…å« 10 ä¸ªè¶…å¤§è™šæ‹Ÿç­›é€‰åº“çš„åœ°ç‹±çº§æµ‹è¯•ä¸­ï¼Œå®ƒçš„æˆåŠŸç‡æ˜¯å…¶ä»–ä»»ä½•é‡æ‰“åˆ†ç­–ç•¥çš„**ä¸¤å€**ã€‚å¯¹äºé‚£äº›æƒ³åœ¨ç™¾ä¸‡çº§åŒ–åˆç‰©åº“é‡Œæ·˜å®çš„ç ”å‘äººå‘˜æ¥è¯´ï¼Œè¿™ç®€ç›´å°±æ˜¯å¼€äº†é€è§†æŒ‚ã€‚
**ç‚¹è¯„**ï¼šä¸ä»…å‡†ï¼Œè€Œä¸”å¿«ã€‚è¿™ç§åŸºç¡€æ¨¡å‹çš„å‡ºç°ï¼Œæ„å‘³ç€ AI åˆ¶è¯æ­£ä»"ç‚’ä½œ"èµ°å‘"å·¥ä¸šçº§å®æˆ˜"ã€‚

### 2. [MAProtï¼šå½“å¤šä¸ª AI "ç‰¹å·¥"ä¸€èµ·è®¾è®¡è›‹ç™½è´¨](https://www.biorxiv.org/content/10.64898/2026.01.13.699365v1?rss=1)
**è›‹ç™½è´¨è®¾è®¡ä¸€ç›´æœ‰ä¸ªä¸¤éš¾ï¼šç»“æ„ç¨³å®šçš„ä¸ä¸€å®šæœ‰åŠŸèƒ½ï¼Œæœ‰åŠŸèƒ½çš„ä¸ä¸€å®šæŠ˜å å¾—å¥½ã€‚**
ä¸ºäº†è§£å†³è¿™ä¸ªé—®é¢˜ï¼Œç ”ç©¶å›¢é˜Ÿæå‡ºäº† MAProtï¼Œè¿™æ˜¯ä¸€ä¸ª**å¤šæ™ºèƒ½ä½“ï¼ˆMulti-Agentï¼‰**ç³»ç»Ÿã€‚å°±åƒç»„å»ºäº†ä¸€ä¸ªä¸“å®¶å›¢é˜Ÿï¼Œä¸€ä¸ª AI è´Ÿè´£ç¡®ç»“æ„ç¨³å›ºï¼ˆåŸºäºç»“æ„ï¼‰ï¼Œå¦ä¸€ä¸ª AI è´Ÿè´£ç¡®ä¿åŠŸèƒ½å¼ºå¤§ï¼ˆåŸºäºè¯­è¨€æ¨¡å‹ï¼‰ï¼Œæœ€åè¿˜æœ‰ä¸€ä¸ª"è°ˆåˆ¤ä¸“å®¶"æ¥å¹³è¡¡ä¸¤è€…çš„å†²çªã€‚ç»“æœæ˜¾ç¤ºï¼Œè¿™ç§"å·¦å³äº’æ"çš„æ¨¡å¼åœ¨æŠ—ä½“è®¾è®¡ç­‰ä»»åŠ¡ä¸Šå®Œçˆ†äº†å•æ‰“ç‹¬æ–—çš„æ¨¡å‹ã€‚
**ç‚¹è¯„**ï¼šAgentï¼ˆæ™ºèƒ½ä½“ï¼‰åä½œæ˜¯ä»Šå¹´ AI çš„å¤§è¶‹åŠ¿ï¼Œç°åœ¨ç»ˆäºå·åˆ°ç”Ÿç‰©å­¦é¢†åŸŸäº†ï¼ŒååŒæ•ˆåº”çœŸé¦™ã€‚

### 3. [Nature é‡ç£…ï¼šç»™è¡€ç³–æ•°æ®è£…ä¸Š"å¤§è„‘"](https://www.nature.com/articles/s41586-025-09925-9)
**å¦‚æœä½ è§‰å¾—è¿ç»­è¡€ç³–ç›‘æµ‹ï¼ˆCGMï¼‰åªæ˜¯ä¸€å †å†·å†°å†°çš„æ•°å­—ï¼Œé‚£å°±é”™äº†ã€‚**
Nature ä»Šå¤©åˆŠç™»äº†ä¸€ä¸ªé’ˆå¯¹ CGM æ•°æ®çš„**åŸºç¡€æ¨¡å‹**ã€‚è¿™å°±å¥½æ¯”ç»™è¡€ç³–ä»ªè£…äº†ä¸ª GPTï¼Œå®ƒä¸ä»…èƒ½çœ‹æ‡‚å½“ä¸‹çš„è¡€ç³–ï¼Œè¿˜èƒ½æ ¹æ®æµ·é‡çš„å†å²æ•°æ®ï¼Œç²¾å‡†é¢„æµ‹æœªæ¥çš„æ³¢åŠ¨ã€‚è¿™ä¸æ˜¯ç®€å•çš„çº¿æ€§å›å½’ï¼Œè€Œæ˜¯çœŸæ­£ç†è§£äº†ä»£è°¢è§„å¾‹ã€‚
**ç‚¹è¯„**ï¼šè¿™æ˜¯æ•°å­—ç–—æ³•çš„ä¸€å¤§æ­¥ã€‚ä»¥åç³–å°¿ç—…ç®¡ç†çš„å»ºè®®å¯èƒ½æ¯”å†…åˆ†æ³Œç§‘åŒ»ç”Ÿè¿˜è¦åŠæ—¶å’Œä¸ªæ€§åŒ–ã€‚

### 4. [LLM è·¨ç•Œï¼šç”¨è¯­è¨€æ¨¡å‹"çŒœ"å‡ºæœªçŸ¥ä»£è°¢ç‰©](https://www.nature.com/articles/s41586-025-09969-x)
**ç”Ÿç‰©ä½“å†…çš„ä»£è°¢ç‰©å¤šå¦‚ç‰›æ¯›ï¼Œå¾ˆå¤šè‡³ä»Šéƒ½æ˜¯"é»‘æˆ·"ã€‚**
Nature å‘è¡¨çš„è¿™é¡¹ç ”ç©¶éå¸¸æœ‰æƒ³è±¡åŠ›ï¼Œä»–ä»¬ç›´æ¥ç”¨**è¯­è¨€æ¨¡å‹ï¼ˆLanguage Modelsï¼‰**æ¥é¢„æµ‹å’Œå‘ç°å“ºä¹³åŠ¨ç‰©ä½“å†…æœªçŸ¥çš„ä»£è°¢ç‰©ã€‚å°±åƒ AI èƒ½é¢„æµ‹ä¸‹ä¸€ä¸ªå•è¯ä¸€æ ·ï¼Œè¿™ä¸ªæ¨¡å‹é€šè¿‡å­¦ä¹ åŒ–å­¦ç»“æ„çš„"è¯­æ³•"ï¼ŒæˆåŠŸé¢„æµ‹å¹¶å‘ç°äº†ä¸€ç³»åˆ—ä»¥å‰æœªè¢«è®°å½•çš„ä»£è°¢äº§ç‰©ã€‚
**ç‚¹è¯„**ï¼šåŒ–å­¦è¯­è¨€ä¹Ÿæ˜¯è¯­è¨€ã€‚ç”¨ NLPï¼ˆè‡ªç„¶è¯­è¨€å¤„ç†ï¼‰çš„æ€è·¯å»è§£æ„ç”Ÿç‰©åŒ–å­¦ï¼Œè¿™æ¡è·¯è¶Šèµ°è¶Šå®½äº†ã€‚

### 5. [åŸºå› ç»„å¤§æ¨¡å‹å¤ªæ…¢ï¼Ÿ"æŠ•æœºè§£ç "æ¥åŠ é€Ÿ](https://www.biorxiv.org/content/10.64898/2026.01.13.699044v1?rss=1)
**ç©è¿‡ç”Ÿç‰©å¤§æ¨¡å‹ï¼ˆå¦‚ DNAGPTï¼‰çš„éƒ½çŸ¥é“ï¼Œç”Ÿæˆé•¿åºåˆ—æ—¶ç­‰å¾…çš„æ—¶é—´è¶³å¤Ÿå–å®Œä¸€æ¯å’–å•¡ã€‚**
ç°åœ¨ï¼Œæœ‰å›¢é˜ŸæŠŠå¤§æ¨¡å‹åœˆæµè¡Œçš„**"æŠ•æœºè§£ç "ï¼ˆSpeculative Decodingï¼‰**æŠ€æœ¯æ¬åˆ°äº†åŸºå› ç»„æ¨¡å‹ä¸Šã€‚åŸç†å¾ˆç®€å•ï¼šç”¨ä¸€ä¸ªå°æ¨¡å‹å¿«é€ŸçŒœï¼Œå¤§æ¨¡å‹è´Ÿè´£æ‰¹æ”¹ï¼ŒçŒœå¯¹äº†ç›´æ¥ç”¨ï¼ŒçŒœé”™äº†å†æ”¹ã€‚æµ‹è¯•è¡¨æ˜ï¼Œåœ¨ä¸ç‰ºç‰²å‡†ç¡®ç‡çš„æƒ…å†µä¸‹ï¼Œæ¨ç†é€Ÿåº¦æœ€é«˜æå‡äº† **100%**ã€‚
**ç‚¹è¯„**ï¼šå¤©ä¸‹æ­¦åŠŸï¼Œå”¯å¿«ä¸ç ´ã€‚åªæœ‰æŠŠæ¨ç†æˆæœ¬é™ä¸‹æ¥ï¼ŒåŸºå› ç»„å¤§æ¨¡å‹æ‰èƒ½çœŸæ­£æ™®åŠåˆ°ä¸´åºŠå’Œå®éªŒå®¤ã€‚

### 6. [Spa3Dï¼šæŠŠç»„ç»‡åˆ‡ç‰‡"æ‹¼"æˆ 3D ä¸–ç•Œ](https://www.biorxiv.org/content/10.64898/2026.01.13.699328v1?rss=1)
**ç°åœ¨çš„ç©ºé—´è½¬å½•ç»„æŠ€æœ¯å¤§å¤šæ˜¯ 2D çš„ï¼Œå°±åƒåœ¨çœ‹åœ°å›¾è€Œä¸æ˜¯çœ‹åœ°çƒä»ªã€‚**
æ–°æ¨å‡ºçš„ Spa3D å·¥å…·ï¼Œåˆ©ç”¨å›¾å·ç§¯ç¥ç»ç½‘ç»œï¼ˆGCNï¼‰ï¼Œèƒ½æŠŠå¤šå¼  2D çš„åˆ‡ç‰‡æ•°æ®"è„‘è¡¥"å¹¶é‡æ„æˆ**3D ç©ºé—´ç»“æ„**ã€‚è¿™ä¸ä»…ä»…æ˜¯å¥½çœ‹ï¼Œå®ƒèƒ½å¸®ä½ çœ‹åˆ°ç»†èƒåœ¨ç«‹ä½“ç©ºé—´é‡Œæ˜¯æ€ä¹ˆäº¤æµçš„ï¼Œç”šè‡³èƒ½å‘ç° 2D è§†è§’ä¸‹å®Œå…¨çœ‹ä¸åˆ°çš„å‘è‚²è½¨è¿¹ã€‚
**ç‚¹è¯„**ï¼šå‡ç»´æ”»å‡»ã€‚å¯¹äºç ”ç©¶å™¨å®˜å‘è‚²å’Œè‚¿ç˜¤å¾®ç¯å¢ƒçš„äººæ¥è¯´ï¼Œè¿™æ˜¯ä¸€ä¸ªèƒ½çœ‹åˆ°"ä¸Šå¸è§†è§’"çš„å·¥å…·ã€‚

### 7. [Sequence-based GenAIï¼šå‡­ç©ºè®¾è®¡è‰²æ°¨é…¸åˆé…¶](https://www.nature.com/articles/s41467-026-68384-6)
**ä»¥å‰æ”¹é€ é…¶é "å®šå‘è¿›åŒ–"ï¼ˆä¹Ÿå°±æ˜¯ç–¯ç‹‚è¯•é”™ï¼‰ï¼Œç°åœ¨ AI è¯´ï¼šæˆ‘ç›´æ¥ç”»ä¸€ä¸ªå§ã€‚**
ç ”ç©¶äººå‘˜å¼€å‘äº†ä¸€ç§åŸºäºåºåˆ—çš„**ç”Ÿæˆå¼ AI**ï¼Œä¸“é—¨ç”¨æ¥è®¾è®¡å¤šåŠŸèƒ½çš„è‰²æ°¨é…¸åˆé…¶ã€‚è¿™äº› AI è®¾è®¡å‡ºæ¥çš„é…¶ï¼Œåœ¨è‡ªç„¶ç•Œä¸­æ ¹æœ¬ä¸å­˜åœ¨ï¼Œä½†åŠŸèƒ½å´æ¯«ä¸é€Šè‰²ï¼Œç”šè‡³å…·å¤‡äº†ç§‘å­¦å®¶æƒ³è¦å®šåˆ¶çš„ç‰¹æ€§ã€‚
**ç‚¹è¯„**ï¼šåˆæˆç”Ÿç‰©å­¦çš„æ ¸å¿ƒæ„¿æ™¯â€”â€”"åƒå†™ä»£ç ä¸€æ ·è®¾è®¡ç”Ÿå‘½"ï¼Œæ­£åœ¨è¢« GenAI ä¸€è¡Œè¡Œå®ç°ã€‚

### 8. [FA-DeepMSMï¼šAI é¢„åˆ¤è„‘èƒ¶è´¨ç˜¤ç”Ÿå­˜æœŸ](https://www.nature.com/articles/s41598-025-34134-9)
**èƒ¶è´¨ç˜¤æ˜¯æå…¶å‡¶é™©çš„è„‘è‚¿ç˜¤ï¼Œé¢„æµ‹æ‚£è€…è¿˜èƒ½æ´»å¤šä¹…ä¸€ç›´æ˜¯ä¸ªç„å­¦ã€‚**
FA-DeepMSM æ¨¡å‹å¼•å…¥äº†"å°‘æ ·æœ¬å­¦ä¹ "å’Œå¤šæ¨¡æ€æ•°æ®ï¼Œä¸“é—¨ç”¨æ¥è§£å†³è¿™ä¸ªé—®é¢˜ã€‚å®ƒä¸ä»…ç»“åˆäº†å½±åƒã€åŸºå› ç­‰å¤šç»´åº¦æ•°æ®ï¼Œè¿˜èƒ½ç»™å‡º**å¯è§£é‡Šæ€§**çš„é¢„æµ‹ç»“æœã€‚è¿™å°±å¾ˆå…³é”®äº†ï¼ŒåŒ»ç”Ÿä¸ä»…çŸ¥é“ç»“æœï¼Œè¿˜èƒ½çŸ¥é“ AI ä¸ºä»€ä¹ˆè¿™ä¹ˆåˆ¤ã€‚
**ç‚¹è¯„**ï¼šå¯è§£é‡Šæ€§æ˜¯åŒ»ç–— AI çš„ç”Ÿæ­»çº¿ã€‚é»‘ç›’æ¨¡å‹å†å‡†åŒ»ç”Ÿä¹Ÿä¸æ•¢ç”¨ï¼Œè¿™ç§èƒ½è§£é‡Š"ä¸ºä»€ä¹ˆ"çš„æ¨¡å‹æ‰æ˜¯ä¸´åºŠéœ€è¦çš„ã€‚

### 9. [å¤§æµ·æé’ˆï¼šç”¨"å¼‚å¸¸æ£€æµ‹"å‘ç°å…³é”®ç¨€æœ‰ç»†èƒ](https://www.biorxiv.org/content/10.64898/2026.01.12.699092v1?rss=1)
**åšå•ç»†èƒæµ‹åºæ—¶ï¼Œå¤§å®¶ä¹ æƒ¯çœ‹"èšç±»"ï¼Œä½†çœŸæ­£å¯¼è‡´ç–¾ç—…çš„å¾€å¾€æ˜¯é‚£äº›èä¸è¿›åœˆå­çš„"æ€ªèƒ"ã€‚**
è¿™ä¸ªæ–°æ¡†æ¶åå…¶é“è€Œè¡Œä¹‹ï¼Œä¸“é—¨æŠ“**ç¦»ç¾¤ç‚¹ï¼ˆOutliersï¼‰**ã€‚åœ¨ COVID-19 æ ·æœ¬çš„æµ‹è¯•ä¸­ï¼Œå®ƒç²¾å‡†æªå‡ºäº†ä¸€ç¾¤é«˜è¡¨è¾¾ç»†èƒæ¯’æ€§æ ‡è®°çš„å…ç–«ç»†èƒï¼Œè¿™äº›ç»†èƒåœ¨é‡ç—‡æ‚£è€…é‡Œç‰¹åˆ«å¤šï¼Œä½†ç”¨å¸¸è§„æ–¹æ³•å¾ˆå®¹æ˜“è¢«å¿½ç•¥ã€‚
**ç‚¹è¯„**ï¼šçœŸç†å¾€å¾€æŒæ¡åœ¨å°‘æ•°ï¼ˆç»†èƒï¼‰æ‰‹ä¸­ã€‚è¿™ä¸ªå·¥å…·æé†’æˆ‘ä»¬ï¼Œåˆ«æ€»ç›¯ç€å¹³å‡å€¼ï¼Œè¾¹ç¼˜æ•°æ®é‡Œè—ç€é‡‘çŸ¿ã€‚

### 10. [AutoBioKGï¼šå…¨è‡ªåŠ¨æ„å»ºç”Ÿç‰©åŒ»å­¦çŸ¥è¯†å›¾è°±](https://www.biorxiv.org/content/10.64898/2026.01.14.699420v1?rss=1)
**ç”Ÿç‰©åŒ»å­¦è®ºæ–‡æ¯å¤©å‘å‡ åƒç¯‡ï¼Œå…‰é äººè¯»æ—©å°±è¯»ä¸è¿‡æ¥äº†ã€‚**
AutoBioKG æ˜¯ä¸€ä¸ªç«¯åˆ°ç«¯çš„æ¡†æ¶ï¼Œèƒ½è‡ªåŠ¨ä»æµ·é‡æ–‡çŒ®ä¸­æå–ä¿¡æ¯ï¼Œæ„å»º**ä¸Šä¸‹æ–‡æ„ŸçŸ¥**çš„çŸ¥è¯†å›¾è°±ã€‚æœ€éªšçš„æ˜¯ï¼Œå®ƒåœ¨é›¶æ ·æœ¬ï¼ˆZero-shotï¼‰æµ‹è¯•ä¸‹ï¼Œæ¯”ç°åœ¨æœ€å…ˆè¿›çš„å¤§æ¨¡å‹ï¼ˆLLMï¼‰è¿˜è¦å‡†ï¼Œç‰¹åˆ«æ˜¯åœ¨å›ç­”å¤æ‚çš„ç”Ÿç‰©åŒ»å­¦é—®é¢˜æ—¶ã€‚
**ç‚¹è¯„**ï¼šè¿™æ˜¯ç§‘ç ”äººå‘˜çš„"ç¬¬äºŒå¤§è„‘"ã€‚ä»¥ååš Literature Reviewï¼Œå¯èƒ½å°±æ˜¯ä¸€é”®ç”Ÿæˆçš„äº‹äº†ã€‚

## **ğŸ“Œ å€¼å¾—å…³æ³¨**

**[å·¥å…·]** [DeepPurpose: æ·±åº¦å­¦ä¹ è¯ç‰©å‘ç°å·¥å…·ç®±](https://github.com/kexinhuang12345/DeepPurpose) - é›†æˆäº† DTIã€DDI ç­‰å¤šç§é¢„æµ‹åŠŸèƒ½çš„å¼€æºåº“ï¼Œè™½ç„¶å‘å¸ƒæœ‰ä¸€æ®µæ—¶é—´äº†ï¼Œä½†ä¾ç„¶æ˜¯ AI åˆ¶è¯å…¥é—¨çš„ç¥å™¨ã€‚

**[å·¥å…·]** [SemiBin: è‡ªç›‘ç£å­¦ä¹ æå®šå®åŸºå› ç»„](https://github.com/BigDataBiology/SemiBin) - ç”¨æ·±åº¦å­¦ä¹ ç»™å®åŸºå› ç»„åˆ†ç®±ï¼ˆBinningï¼‰ï¼Œæ•ˆæœæ¯”ä¼ ç»Ÿæ–¹æ³•å¥½ä¸å°‘ï¼Œåšå¾®ç”Ÿç‰©ç»„çš„åŒå­¦å¯ä»¥è¯•è¯•ã€‚

**[ç ”ç©¶]** [AI è¾…åŠ©è´¥è¡€ç—‡æ­»äº¡ç‡é¢„æµ‹](https://www.nature.com/articles/s41598-026-36245-3) - ç»“åˆäº†è”é‚¦å­¦ä¹ ï¼ˆä¿æŠ¤éšç§ï¼‰å’Œå¯è§£é‡Š AIï¼Œè¯•å›¾è§£å†³ ICU é‡Œæœ€æ£˜æ‰‹çš„è´¥è¡€ç—‡é¢„è­¦é—®é¢˜ã€‚

**[ç ”ç©¶]** [PROMIS: æ— éœ€é…å¯¹æ ·æœ¬çš„ MSI æ£€æµ‹](https://www.biorxiv.org/content/10.64898/2026.01.13.699258v1?rss=1) - è¿™ä¸ªç®—æ³•å‰å®³åœ¨ä¸éœ€è¦æ­£å¸¸ç»„ç»‡åšå¯¹ç…§ï¼Œå°±èƒ½ä»è‚¿ç˜¤æµ‹åºæ•°æ®é‡Œåˆ¤æ–­å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ï¼Œä¸´åºŠåº”ç”¨æ½œåŠ›å·¨å¤§ã€‚

**[ç ”ç©¶]** [stochastic LASSO: å¤„ç†è¶…é«˜ç»´åŸºå› ç»„æ•°æ®](https://www.nature.com/articles/s41598-026-35273-3) - ä¹Ÿå°±æ˜¯æ•°å­¦å®¶å‡ºæ‰‹å¸®ç”Ÿç‰©å­¦å®¶é™ç»´ï¼Œä¸“é—¨å¯¹ä»˜é‚£ç§å˜é‡æ¯”æ ·æœ¬å¤šå¾—å¤šçš„åŸºå› ç»„æ•°æ®ã€‚

## **ğŸ”® AIç”Ÿå‘½ç§‘å­¦è¶‹åŠ¿é¢„æµ‹**

### ç”Ÿç‰©å¤§æ¨¡å‹"æ¨ç†åŠ é€Ÿ"æˆ˜å½¹æ‰“å“
- **é¢„æµ‹æ—¶é—´**ï¼š2026å¹´Q2
- **é¢„æµ‹æ¦‚ç‡**ï¼š85%
- **é¢„æµ‹ä¾æ®**ï¼šä»Šæ—¥æ–°é—»[åŸºå› ç»„æ¨¡å‹æŠ•æœºè§£ç ](https://www.biorxiv.org/content/10.64898/2026.01.13.699044v1?rss=1) + éšç€ Bio-LLM å‚æ•°é‡æ¿€å¢ï¼Œæ¨ç†æˆæœ¬æˆä¸ºæœ€å¤§ç“¶é¢ˆï¼Œç±»ä¼¼"æŠ•æœºè§£ç "çš„åŠ é€ŸæŠ€æœ¯å°†æˆä¸ºè¡Œä¸šæ ‡é…ã€‚

### "å¤šæ™ºèƒ½ä½“ï¼ˆMulti-Agentï¼‰"é‡å¡‘è›‹ç™½è´¨è®¾è®¡æµç¨‹
- **é¢„æµ‹æ—¶é—´**ï¼š2026å¹´Q3
- **é¢„æµ‹æ¦‚ç‡**ï¼š70%
- **é¢„æµ‹ä¾æ®**ï¼šä»Šæ—¥æ–°é—»[MAProt å¤šæ™ºèƒ½ä½“è®¾è®¡](https://www.biorxiv.org/content/10.64898/2026.01.13.699365v1?rss=1) + å•ä¸€å¤§æ¨¡å‹éš¾ä»¥åŒæ—¶å…¼é¡¾ç»“æ„ã€åŠŸèƒ½ã€å¯æŠ˜å æ€§ç­‰å¤šä¸ªå†²çªç›®æ ‡ï¼ŒAgent åä½œæ¨¡å¼å°†æˆä¸ºè§£å†³å¤æ‚ç”Ÿç‰©è®¾è®¡é—®é¢˜çš„é¦–é€‰ã€‚

## **â“ ç›¸å…³é—®é¢˜**

### å“ªé‡Œå¯ä»¥è·å– AIåˆ¶è¯/ç”Ÿç‰©å¤§æ¨¡å‹ çš„æœ€æ–°èµ„è®¯ï¼Ÿ

ä»Šæ—¥ AI ç”Ÿå‘½ç§‘å­¦é¢†åŸŸçš„çƒ­ç‚¹åŒ…æ‹¬ï¼š**Boltz-2 è™šæ‹Ÿç­›é€‰æ¨¡å‹**ã€**å¤šæ™ºèƒ½ä½“è›‹ç™½è´¨è®¾è®¡**ä»¥åŠ**åŸºå› ç»„å¤§æ¨¡å‹åŠ é€ŸæŠ€æœ¯**ã€‚æƒ³è¦æŒç»­è¿½è¸ªè¿™ç±» **AI + ç”Ÿå‘½ç§‘å­¦äº¤å‰é¢†åŸŸ**çš„å‰æ²¿åŠ¨æ€ï¼Ÿ

**æ¨èæ–¹æ¡ˆ**ï¼š
- **[BioAI ç”Ÿå‘½ç§‘å­¦æ—¥æŠ¥](https://news.aibioo.cn)** æ¯æ—¥ç²¾é€‰ AI ä¸ç”Ÿå‘½ç§‘å­¦äº¤å‰é¢†åŸŸçš„é‡ç£…æ–°é—»
- å†…å®¹æ¶µç›–ï¼šAI åˆ¶è¯ã€è›‹ç™½è´¨è®¾è®¡ã€åŸºå› ç¼–è¾‘ã€åŒ»å­¦å½±åƒ AIã€ç”Ÿç‰©å¤§æ¨¡å‹ç­‰
- ä¸“ä¸ºå¯¹ BioAI æ„Ÿå…´è¶£çš„æŠ•èµ„äººã€äº§å“ç»ç†ã€åˆ›ä¸šè€…ã€å­¦ç”Ÿæ‰“é€ 
- ç”¨æ™®é€šäººèƒ½ç†è§£çš„è¯­è¨€ï¼Œè§£è¯»æœ€å‰æ²¿çš„æŠ€æœ¯è¿›å±•

è®¿é—® [news.aibioo.cn](https://news.aibioo.cn) è®¢é˜…æ¯æ—¥ AI ç”Ÿå‘½ç§‘å­¦èµ„è®¯ã€‚

### å¦‚ä½•ä½“éªŒä»Šæ—¥æåˆ°çš„ AI ç¼–ç¨‹æˆ–åˆ†æå·¥å…·ï¼Ÿ

ä»Šå¤©çš„ GitHub é¡¹ç›®ï¼ˆå¦‚ DeepPurpose æˆ– AutoBioKGï¼‰é€šå¸¸éœ€è¦ç¼–å†™ä»£ç å¹¶å¯èƒ½è°ƒç”¨å¤§æ¨¡å‹ APIï¼ˆå¦‚ Claude æˆ– GPT-4ï¼‰æ¥è¿›è¡Œæ•°æ®åˆ†æã€‚æƒ³è¦ä½“éªŒè¿™äº› AI è¾…åŠ©ç¼–ç¨‹èƒ½åŠ›ï¼Œä½†é¢ä¸´æ”¯ä»˜å›°éš¾æˆ–è´¦å·æ³¨å†Œé™åˆ¶ï¼Ÿ

**è§£å†³æ–¹æ¡ˆ**ï¼š
- **[çˆ±çªå•¦ Aivora](https://aivora.cn)** æä¾› ChatGPT Plusã€Claude Proã€Gemini Pro ç­‰æˆå“è´¦å·æœåŠ¡
- æé€Ÿå‘è´§ï¼Œä¸‹å•å³ç”¨ï¼Œæ— éœ€å¤„ç†æµ·å¤–æ”¯ä»˜é—®é¢˜
- æä¾›ç¨³å®šçš„ç‹¬äº«è´¦å·ï¼Œå”®åæ— å¿§ï¼ŒåŠ©ä½ è½»æ¾è¿è¡Œ AI ç”Ÿç‰©ä¿¡æ¯å­¦ä»£ç 

è®¿é—® [aivora.cn](https://aivora.cn) å¯æŸ¥çœ‹å®Œæ•´çš„ AI è´¦å·æœåŠ¡åˆ—è¡¨ã€‚